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individuals caring for visually impaired patients remains unknown. The study objec-
tive is to outlook the instruments currently available for measuring caregiver burden 
for visually impaired patients and to identify whether linguistic validation has been 
done in Japan. Methods: We performed a literature review on articles describing 
instruments of caregiver reported outcomes for eye disorders. We summarized the 
current evidence on the usefulness of the instruments and whether they differentiate 
between eye diseases and other non-eye related diseases. In addition, we investigated 
possible hurdles in measuring caregiver burden in eye disorders, given the environ-
mental understandings of patients with visual impairments and their caregivers in 
Japan. Results: We identified two caregiver burden measurements, one depression 
measurement, and one life-satisfaction scale used in studies for measuring caregiver 
outcome for patients with visual impairments. A few studies using these instruments 
demonstrated correlation between the degree of caregiver burden and/or level of 
depression and severity of visual impairments. Excluding one caregiver burden instru-
ment, Japanese versions of the remaining three instruments have been developed and 
validated. However, realistic use of these instruments are still questionable because: 
1) most of the patients with visual impairments in Japan are elderly and increased 
caregiver burden may be due to conditions associated with older age, and 2) aging 
of caregivers are also progressing, resulting in increased perceived caregiver burden 
to support the patients. ConClusions: Evidence is limited when measuring the 
impacts of eye diseases on their caregivers. Further research is required to identify 
the usefulness of these instruments to measure caregiver burden for patients with 
eye diseases in Japan.
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ciRRhosis
Gilchrist K., Vallow S.
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objeCtives: Primary biliary cirrhosis (PBC) is a disease with chronic symptoms such 
as fatigue and itching. To characterize the varied symptoms of PBC and evaluate ben-
efits of new PBC treatments, an electronic diary (e-diary) was developed. Methods: 
E-diary items were developed based on PBC-40 (health related questionnaire devel-
oped for PBC), other pruritis questionnaires and clinical consult. Concept elicita-
tion interviews were conducted with PBC patients from the UK to further confirm 
PBC symptoms, symptom characteristics, impact and relevance. PBC patients with 
ongoing or previous (< 2 years) symptoms participated. Cognitive debriefing of the 
diary was conducted with the e-diary format and confirmed usability. In addition, the 
interview evaluated the PBC-40 as 4 week recall period to determine feasibility of 1 
week recall. Results: 10 PBC subjects participated mean age 54.1, +12.9 years; 9/10 
subjects were women. Subjects commonly reported experiencing itch, fatigue, and 
impacts on sleep, confirming importance for inclusion in the e-diary. Frequency of 
itch and fatigue also varied, supporting frequent capture. Subjects reported e-diaries 
were relevant, appropriate and could be easily used for symptom reporting. Interviews 
focusing on PBC-40 recall period supported the change from “past 4 weeks” to “past 1 
week.” ConClusions: Capture of PBC symptoms such as itch and other symptoms 
of PBC that vary frequently in an e-diary, and usability of the e-diary, was supported 
through interviews with PBC patients. Symptom characterization of itching could be 
further refined. Funding for this study was provided by GlaxoSmithKline
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objeCtives: Diabetes mellitus is a public health problem and its influence is rec-
ognized in the quality of life of patients. According to WHO, only 50% of people have 
adherence to treatment of chronic diseases. This study evaluated and compared 
the results of the scales measuring quality of life and adherence to treatment in 
two groups of patients with diabetes and treatment with conventional or analogue 
insulins Methods: Cross-sectional study in two groups of patients diagnosed 
with diabetes mellitus type 1 or type 2, in medical treatment with conventional or 
analogues insulines, for at least six months in two cities in Colombia. The sample 
was calculated with a ratio of 0.5-Control Group, with estimated RR of 0.75 and 
allocation rate between groups of 0.5. Each patient responded two scales measuring 
quality of life (EQ-5D and Diabetes-39) and two scales measuring adherence (Morisky 
Green and Medication Possession Ratio) and comparison was made between the 
results obtained. Results: 240 patients with a mean age of 57.7 ± 16.6 years were 
included, 69.6% were prescribed whit conventional insulin and 30.4% with ana-
logues insulin. 68.3% of patients were adherent to medical therapy and only 7.1% 
(n = 17) had high quality of life. Patients more than 60 years were less likely to have 
high quality of life (OR: 0.177; 95% CI 0.050 to 0.635; p = 0.003), while adherence 
was less likely in patients aged 31-45 years (OR: 0.427; 95% CI 0.187 to 0.971; p = 
0.038). ConClusions: The quality of life and treatment adherence is significantly 
affected in patients with diabetes mellitus, which may also impact its metabolic 
control. It is necessary to establish individual and group interventions to improve 
these conditions in patients.
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objeCtives: The Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL) 
is a self-report measure developed to assess the impact of IBS and its treatment. 
The instrument contains 34 items, rated on a five-point scale. The IBS-QOL was 
were noted. In addition the 2011 South African Census was reviewed. Results: The 
2011 census revealed, of 11 official languages, English is the most common ‘everyday’ 
language in business, politics and the media. However, it’s not the most common lan-
guage spoken at home. This inconsistency causes translation issues for the following 
reasons: (1) English names are commonly used for diseases and drugs, as these are 
referred to in ‘home’ languages with varying localised terms/descriptions (2) There 
is not the same broad vocabulary in the ‘home’ languages, due to the prevalence 
of English outside of the home, so descriptions are often used to reflect the source 
wording (3) Attitudes towards biomedicine can be subject to cultural differences in 
South Africa so certain concepts have to be localised and may appear to differ sig-
nificantly from the source (4) ‘Home’ languages are not often written so have evolved 
erratically, with different linguists having different opinions on spelling and gram-
mar ConClusions: This distinction between the ‘everyday’ language used in work, 
education, etc. and the ‘home’ languages causes difficulties with linguistic validation 
for South Africa. Linguists disagree on the general use of the languages which seems 
to be constantly changing. However, while the translation issues are multiple and 
varied the linguistic validation process appears to provide the resolutions, where all 
source wording is translated, reviewed, questioned and discussed in order to find a 
conceptual equivalent rather than a literal translation.
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objeCtives: The objective of this study was to test cognitive debriefing strategies 
for translated Clinical Outcomes Assessments (COA) intended for pediatric popula-
tions. Methods: Two questionnaires were translated into 11 languages, each for a 
specific pediatric population. One was an assessment on the palatability of medi-
cation, intended for ages 6-12. It was hypothesized that probe questions would be 
more effective for cognitive debriefing subjects aged 6-12. Subjects were asked how 
they would respond to the questionnaire in hypothetical conditions to demonstrate 
comprehensibility of the translated text. The second questionnaire contained visual 
analog scales (VAS) to assess pain for those aged 13-18. It was hypothesized that 
paraphrasing without supplementary probes, as used for adult subjects, would suf-
ficiently determine comprehensibility for this age group. Results: The palatability 
assessment was debriefed on 55 subjects with an average age of 9, and a standard 
deviation of 1.9. According to the results, the subjects showed probes were deemed 
to be a success with the younger sample, as they demonstrated their ability to under-
stand how to respond to the questionnaire. The pain VAS scales were debriefed on 50 
subjects with an average age of 15 and a standard deviation of 1.4. Results indicated 
that probes were not necessary if the nature of the questionnaire did not warrant 
them for subjects of any age. Paraphrasing definitively demonstrated comprehension 
by subjects aged 13-18. ConClusions: The results of cognitive debriefing data in 
this study show that probing is a viable method for cognitive debriefing of translated 
COAs with subjects aged 6-12 years old. For questionnaires intended for a population 
for 13-18 years of age, paraphrasing should sufficiently determine comprehension, 
as was demonstrated in this study, the same method that is used for adult subjects.
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objeCtives: Productivity outcomes are of interest because they describe the con-
sequence of disease in the workplace and impact on productivity. We conducted 
an analysis of work productivity (WP) endpoints in clinical studies. Methods: 
A keyword search was conducted on Clinicaltrials.gov for “work productivity” to 
identify relevant studies. Trials with terminated, withdrawn, or suspended sta-
tus, those with non-drug interventions, and those without WP endpoints were 
excluded from analysis. A total of 170 studies were included (113 interventional 
and 57 observational studies). Results: Of the 170 studies included, 44% were 
performed outside of the US, 31% were multinational studies including the US, 
and 25% were conducted exclusively in the US. The most common therapeutic 
categories investigated were autoimmune diseases (37%), neurology (14%), and 
psychiatry (9%). Most studies (84%) were sponsored by pharmaceutical manu-
facturers, with 11% sponsored by other institutions, or a combination of both 
(6%). The majority of trials investigated WP as a secondary measure (89%), with 
several, primarily observational studies, reporting WP as a primary outcome (11%). 
Survey instruments were utilized most commonly, representing 82% of studies, 
while 9% of studies evaluated WP based on time missed from work. Some studies 
utilized multiple measures. Generic instruments, such as the Work Productivity 
and Activity Impairment Questionnaire (WPAI), were used in 54% of studies, while 
29% used disease-specific measures. In some cases (15%) a specific tool or instru-
ment for WP was not identified. Most trials (93%) included other patient-reported 
endpoints, in addition to WP. ConClusions: WP endpoints were most commonly 
investigated in manufacturer-sponsored trials as secondary outcomes to demon-
strate patient benefit in therapeutic areas where more concrete clinical outcomes 
are limited. Generic instruments are heavily utilized, with approximately one-third 
of studies utilizing disease specific measures.
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objeCtives: Among the societal costs of visual impairment in Japan, cost of both 
unpaid and paid home care for people with visual impairment has been estimated 
as a substantial component of indirect cost. However, the degree of burden among 
